Safety and mid‐term surgical results of anterior urethroplasty with the tissue‐engineered oral mucosa graft MukoCell^®: A single‐center experience

Abstract

Abbreviations & Acronyms AE = adverse event AUA-SS = American Urological Association Symptom Score BMI = body mass index CI = confidence interval FU = follow-up IQR = interquartile range ND = non-definable NOMG = native oral mucosa graft OR = odds ratio PVR = post-void residual Q max = maximum urinary flow rate RUG = retrograde urethrography SD = standard deviation SR = success rate TEOMG = tissue-engineered oral mucosa graft UTI = urinary tract infection VCUG = voiding cystourethrography

Comparison of oral morbidity and mid‐term efficacy of anterior urethroplasty using an autologous tissue‐engineered graft (MukoCell®) versus native oral mucosa graft

“…Our current observational, single‐center study aimed to compare the mid‐term surgical outcomes and the complication rates of augmentation urethroplasty using this new TEOMG versus the classic NOMG, highlighting the comparison regarding complications of both techniques in the oral cavity. It also complements our research group's previous experience with MukoCell®, providing a longer follow‐up (FU) of median 52 months 9 …”

“…On the other hand, 77 patients had undergone augmentation urethroplasty using an autologous TEOMG (Mukocell®), which had been manufactured in an external certified laboratory, following a small oral biopsy harvest from the recipient patient in local anesthesia (Xylocaine 1%) 3 weeks prior. The complete harvesting procedure and surgical utility of Mukocell® in our department have been extensively described previously 9 . The standardized manufacturing procedure of Mukocell® including the pharmacology, pharmacokinetics, toxicology, and tumorigenicity has already been fully analyzed 10 …”

“…In the last decade, a tissue‐engineered oral mucosa graft (TEOMG) called MukoCell® has been introduced and authorized in Germany. Since then, several single‐arm observational urethroplasty series using MukoCell® have been published, showing mid‐term success rates (SR) of 68.8%–84.2% 7–11 . However, to date, no comparative analysis against the use of NOMG has been reported.…”

“…Since then, several single-arm observational urethroplasty series using MukoCell® have been published, showing mid-term success rates (SR) of 68.8%-84.2%. [7][8][9][10][11] However, to date, no comparative analysis against the use of NOMG has been reported. Thus, a non-inferiority of this new TEOMG to the classic NOMG regarding its SR in reconstructive urethral surgery cannot yet be pronounced.…”

Smoking is an independent risk factor for stricture recurrence after the urethroplasty: a systematic review and meta-analysis

“…The detailed screening procedure is displayed in Figure-1 . There were 18 studies (total 5811 patients) contained smoking-stricture recurrence univariate analysis information( 3 , 10 - 26 ), 11 studies (total 3167 patients) contained multivariable analysis information( 10 , 12 , 15 , 16 , 18 - 20 , 27 - 30 ). Out of 20 involved studies, 19 studies are retrospective cohort studies, and only 1 study was prospectively designed.…”